Key facts
- It has raised $1.1M across 1 recorded rounds; the latest was Seed Round ($1.3M) in Oct 2025.
- Notable investors include Creative Destruction Lab, SOSV, IndieBio, Life Science Washington Institute, Reinforced Ventures — 6 tracked in total.
- Primary Bioscience has filed 1 Form D with the SEC, most recently Oct 2025 ($100K sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Primary Bioscience
Funding rounds
1 roundsAbout Primary Bioscience
Developer of a multi-disease diagnostic device designed for comprehensive, multi-biomarker screening. The company's device performs unbiased sequencing of every protein in a sample, including hard-to-detect variations such as single-residue substitutions, splice variants, and post-translational truncations, enabling clients and the healthcare sector with nanopore-based, single-molecule protein sequencing technology.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2023
- Employees
- 2
- Website
- primarybioscience.com/
- Ownership
- Privately Held (backing)
Primary Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Primary Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Primary Bioscience in its N-PORT filings yet. We sweep new filings monthly.